SS-31 Guide

SS-31, also known as elamipretide, MTP-131, or Bendavia in earlier development literature, is a mitochondria-targeted tetrapeptide. The FDA-approved prescription product is Forzinity, an elamipretide injection from Stealth BioTherapeutics. [1][2][8]

The most important status distinction is between the regulated drug and informal peptide-market use. Forzinity has a narrow FDA-approved indication for Barth syndrome under the accelerated approval pathway. Products marketed online as SS-31 research peptides, mitochondrial peptides, or longevity peptides should not be assumed equivalent to Forzinity in identity, purity, sterility, labeling, or legal status. [1][2][3]

Barth syndrome is a rare mitochondrial disorder involving cardiolipin biology. That makes elamipretide scientifically interesting, but it also means the strongest human evidence comes from small rare-disease studies and defined trial settings, not from general wellness, anti-aging, athletic-performance, or fatigue-recovery use. [1][3][4][5]

FDA materials describe Forzinity as a mitochondrial cardiolipin binder. Cardiolipin is a lipid enriched in the inner mitochondrial membrane and is important for mitochondrial structure and energy-generating machinery. [1][2][3][7]

Mechanistic studies describe SS-31 as an amphipathic tetrapeptide that can interact with cardiolipin-containing membranes and alter membrane biophysics. This provides a plausible reason for studying elamipretide in disorders where cardiolipin remodeling, mitochondrial membrane structure, or oxidative stress are central biology. [7]

The mechanism should not be simplified into "repairs mitochondria" or "boosts ATP" as a guaranteed human outcome. Mitochondrial targeting is a pharmacologic rationale; clinical benefit still depends on disease biology, endpoint selection, exposure, safety, and controlled human evidence. [3][6][7]

FDA granted accelerated approval to Forzinity on September 19, 2025, for improving muscle strength in Barth syndrome patients meeting the labeled weight requirement. The approval was based on an intermediate clinical endpoint: knee extensor muscle strength. FDA also required a post-approval randomized confirmatory trial to verify clinical benefit. [1][2][3]

The FDA Drug Trials Snapshot is important because it explains the evidence nuance. In the 12-patient randomized crossover study, Forzinity was not superior to placebo on the original primary endpoints of 6-minute walk distance and the Barth Syndrome Symptom Assessment Total Fatigue Score. Increases in knee extensor strength were observed during the longer open-label extension. [3]

The peer-reviewed TAZPOWER publication reported that the randomized 12-week treatment periods did not meet the primary endpoints, while the open-label extension showed improvements at later time points in 6-minute walk distance and symptom scores. Because open-label extensions lack a concurrent placebo control, they are useful but less definitive than randomized blinded comparisons. [4]

Longer-term TAZPOWER open-label extension data through 168 weeks reported durable functional, cardiac, and biomarker changes in the small group that remained in follow-up, with injection-site reactions among common adverse events. The small sample size and open-label design remain central limitations. [5]

In primary mitochondrial myopathy, the larger MMPOWER-3 randomized trial did not meet its primary endpoints for 6-minute walk distance or fatigue at 24 weeks compared with placebo, although elamipretide was described as generally well tolerated. This is a useful caution against generalizing Barth syndrome approval to all mitochondrial or fatigue-related conditions. [6]

Common online claims include improved mitochondrial function, reduced fatigue, better endurance, anti-aging effects, neuroprotection, cardioprotection, and faster recovery. The defensible clinical claim is much narrower: an FDA-approved elamipretide product exists for a specific Barth syndrome indication under accelerated approval. [1][2][3]

For Barth syndrome, there is a real regulatory and clinical evidence base, but it is unusually small because the disease is ultra-rare. FDA explicitly framed the approval around an intermediate endpoint and the need for confirmatory evidence, so the evidence should not be overstated. [1][3][4][5]

For primary mitochondrial myopathy, the strongest late-stage randomized evidence did not show improvement on the primary walking or fatigue endpoints. That does not make the mechanism irrelevant, but it does weaken broad claims that SS-31 reliably improves mitochondrial disease symptoms outside the approved indication. [6]

For longevity, athletic performance, recovery, chronic fatigue, neurodegeneration, or general mitochondrial optimization, this draft does not identify FDA-approved indications or definitive human outcome evidence. Such claims should be treated as investigational or speculative unless tied to a specific trial, population, route, endpoint, and product. [6][7]

The Forzinity label lists serious hypersensitivity to elamipretide or any excipient as a contraindication. It also warns that hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention, have been reported and may include skin manifestations and respiratory symptoms. [2][3]

Injection-site reactions were the most common adverse reactions in FDA materials. In the FDA snapshot, local administration reactions, erythema, pain, induration, pruritus, bruising, and urticaria were reported more often with Forzinity than placebo during the randomized trial period. [2][3]

Forzinity contains benzyl alcohol and is not approved for use in neonates. The label warns about benzyl alcohol toxicity in low-birth-weight and preterm neonates exposed to benzyl-alcohol-containing drugs, including serious and fatal reactions. [2]

The label also includes important population-specific limits, including insufficient information for some renal-impairment situations and lack of data in certain pregnancy, lactation, geriatric, and lower-weight pediatric contexts. Those label limits should not be replaced by vendor claims or forum protocols. [2]

Safety findings for regulated Forzinity cannot be assumed to apply to research powders or unapproved SS-31 products. Unapproved products may differ in identity, concentration, sterility, endotoxin burden, impurities, excipients, stability, and storage history. [2][3]

The FDA-approved Forzinity label gives product-specific storage instructions: store refrigerated at 2 to 8 degrees C, do not freeze, and discard opened vials 8 days after first opening. Those details apply to the approved finished drug product, not to research powders or non-approved vials sold as SS-31. [2]

Because this profile is educational, it does not provide injection technique, reconstitution steps, concentration math, cycle plans, route guidance, or purchasing advice. Practical handling belongs to the approved product label, a qualified healthcare professional, or an authorized clinical-trial protocol. [2][3]

A vendor storage note for a peptide powder is not the same as FDA-reviewed stability data for a finished drug. Without regulated manufacturing and labeling, readers cannot verify whether a product has the same active ingredient, formulation, sterility controls, or shelf-life assumptions as Forzinity. [2]